ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2026, Vol. 40 ›› Issue (6): 76-82.
• Airway Allergic Diseases: From Mechanism to Practice • Previous Articles
CHEN Ruien1, ZOU Huamei1, LIAO Yun2, YANG Gui1
CLC Number:
| [1] 刘玉, 李帆, 戴蕙芸, 等. 定点突变优化信号肽对嵌合抗原受体T细胞功能的影响[J]. 生物工程学报, 2024, 40(2): 573-584. DOI:10.13345/j.cjb.230506 [2] Maus M V. CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia[J]. Lancet, 2021, 398(10299): 466-467. DOI: 10.1016/S0140-6736(21)01289-7 [3] Kong Y J, Li J Y, Zhao X Y, et al. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity[J]. Front Immunol, 2025, 15: 1519671. DOI: 10.3389/fimmu.2024.1519671 [4] Esmaeilzadeh A, Tahmasebi S, Athari S S. Chimeric antigen receptor -T cell therapy: applications and challenges in treatment of allergy and asthma[J]. Biomed Pharmacother. 2020, 123: 109685. DOI: 10.1016/j.biopha.2019.109685 [5] Lyu J, Kou F, Men X, et al. The changes in bacterial microbiome associated with immune disorder in allergic respiratory disease[J]. Microorganisms, 2022, 10(10): 2066. DOI: 10.3390/microorganisms10102066 [6] Mohammad Taheri M, Javan F, Poudineh M, et al. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.[J] J Transl Med. 2024;22(1):736. DOI:10.1186/s12967-024-05534-8 [7] Huang T, Bei C Q, Hu Z H, et al. CAR-macrophage: breaking new ground in cellular immunotherapy[J]. Front Cell Dev Biol, 2024, 12: 1464218. DOI: 10.3389/fcell.2024.1464218 [8] Khan A N, Chowdhury A, Karulkar A, et al. Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation[J]. Front Immunol, 2022, 13: 886546. DOI: 10.3389/fimmu.2022.886546 [9] Ma L Y, Dichwalkar T, Chang J Y H, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor[J]. Science, 2019, 365(6449): 162-168. DOI: 10.1126/science.aav8692 [10] Abdeladhim M, Zhang A H, Kropp L E, et al. Engineered ovalbumin-expressing regulatory T cells protect against anaphylaxis in ovalbumin-sensitized mice[J]. Clin Immunol, 2019, 207: 49-54. DOI: 10.1016/j.clim.2019.07.009 [11] Ward D E, Fay B L, Adejuwon A, et al. Chimeric antigen receptors based on low affinity mutants of FcεRI re-direct T cell specificity to cells expressing membrane IgE[J]. Front Immunol, 2018, 9: 2231. DOI: 10.3389/fimmu.2018.02231 [12] Chen S S, Chen G Y, Xu F, et al. Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells[J]. Cell Discov, 2022, 8(1): 80. DOI: 10.1038/s41421-022-00433-y [13] Mavi A K, Gaur S, Gaur G, et al. CAR T-cell therapy: reprogramming patient's immune cell to treat cancer[J]. Cell Signal, 2023, 105: 110638. DOI: 10.1016/j.cellsig.2023.110638 [14] Schubert M L, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor(CAR)T-cell therapy[J]. Ann Oncol, 2021, 32(1): 34-48. DOI: 10.1016/j.annonc.2020.10.478 [15] 吴俣, 李佩璐, 葛军, 等. 嵌合抗原受体调节性T细胞免疫疗法在器官移植中的应用[J]. 器官移植, 2020, 11(5): 547-552. DOI: 10.3969/j.issn.1674-7445.2020.05.003 [16] Beheshti S A, Shamsasenjan K, Ahmadi M, et al. CAR Treg: a new approach in the treatment of autoimmune diseases[J]. Int Immunopharmacol, 2022, 102: 108409. DOI: 10.1016/j.intimp.2021.108409 [17] Golubovskaya V, Wu L J. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy[J]. Cancers(Basel), 2016, 8(3): 36. DOI: 10.3390/cancers8030036 [18] Riet T, Chmielewski M. Regulatory CAR-T cells in autoimmune diseases: progress and current challenges[J]. Front Immunol, 2022, 13: 934343. DOI: 10.3389/fimmu.2022.934343 [19] Arjomandnejad M, Kopec A L, Keeler A M. CAR-T regulatory(CAR-treg)cells: engineering and applications[J]. Biomedicines, 2022, 10(2): 287. DOI: 10.3390/biomedicines10020287 [20] Chen T, Wang M Z, Chen Y C, et al. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors[J]. Cancer Cell Int, 2024, 24(1): 133. DOI: 10.1186/s12935-024-03315-3 [21] Vincent R L, Gurbatri C R, Li F D, et al. Probiotic-guided CAR-T cells for solid tumor targeting[J]. Science, 2023, 382(6667): 211-218. DOI: 10.1126/science.add7034 [22] Li Q R, Zhang X Y, Feng Q, et al. Common allergens and immune responses associated with allergic rhinitis in China[J]. J Asthma Allergy, 2023, 16: 851-861. DOI: 10.2147/JAA.S420328 [23] Lambrecht B N, Hammad H. CAR T cells put the brakes on asthma[J]. Nat Immunol, 2024, 25(6): 935-937. DOI: 10.1038/s41590-024-01851-8 [24] Dudek R P, Ma Z Y. CAR T cells for treating severe atopic allergic diseases[J]. Dela J Public Health, 2023, 9(4): 12-15. DOI: 10.32481/djph.2023.11.004 [25] Shamji M H, Valenta R, Jardetzky T, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease[J]. Allergy, 2021, 76(12): 3627-3641. DOI: 10.1111/all.14908 [26] Garman S C, Wurzburg B A, Tarchevskaya S S, et al. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha[J]. Nature, 2000, 406(6793): 259-266. DOI: 10.1038/35018500 [27] Dhaliwal B, Yuan D P, Pang M O Y, et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI[J]. Proc Natl Acad Sci USA, 2012, 109(31): 12686-12691. DOI: 10.1073/pnas.1207278109 [28] 唐思艺, 朱新华. CCR3基因在呼吸道过敏性疾病中对相关炎性细胞的作用研究[J]. 临床耳鼻咽喉头颈外科杂志, 2021, 35(1): 80-84. DOI: 10.13201/j.issn.2096-7993.2021.01.021 [29] Bao Y W, Wu Z K, Zhu X H, et al. The study of the role of purified anti-mouse CD193(CCR3)antibody in allergic rhinitis mouse animal models[J]. Sci Rep, 2024, 14(1): 1059. DOI: 10.1038/s41598-024-51679-3 [30] Zhang Z Q, Bao Y W, Wang H, et al. Artesunate alleviates chronic allergic rhinitis and asthma syndrome via the CCR3/NF-κB pathway: a comprehensive analysis[J]. Int Immunopharmacol, 2025, 166: 115562. doi:10.1016/j.intimp.2025.115562 [31] Dai M N, Zhu X H, Yu J, et al. CCR3 gene knockout in bone marrow cells ameliorates combined allergic rhinitis and asthma syndrome(CARAS)by reducing airway inflammatory cell infiltration and Th2 cytokines expression in mice model[J]. Int Immunopharmacol, 2022, 104: 108509. DOI: 10.1016/j.intimp.2021.108509 [32] 陈高莹. 靶向CCR3的嵌合抗原受体T细胞治疗哮喘的研究[D]. 浙江大学, 2023 [33] Matucci A, Maggi E, Vultaggio A. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma[J]. Respir Med, 2019, 160: 105819. DOI: 10.1016/j.rmed.2019.105819 [34] Pitlick M M, Pongdee T. Combining biologics targeting eosinophils(IL-5/IL-5R), IgE, and IL-4/IL-13 in allergic and inflammatory diseases[J]. World Allergy Organ J, 2022, 15(11): 100707. DOI: 10.1016/j.waojou.2022.100707 [35] Eschenbacher W, Straesser M, Knoeddler A, et al. Biologics for the treatment of allergic rhinitis, chronic rhinosinusitis, and nasal polyposis[J]. Immunol Allergy Clin North Am, 2020, 40(4): 539-547. DOI: 10.1016/j.iac.2020.06.001 [36] Morris E C, Neelapu S S, Giavridis T, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy[J]. Nat Rev Immunol, 2022, 22(2): 85-96. DOI: 10.1038/s41577-021-00547-6 [37] Chohan K L, Siegler E L, Kenderian S S. CAR-T cell therapy: the efficacy and toxicity balance[J]. Curr Hematol Malig Rep, 2023, 18(2): 9-18. DOI: 10.1007/s11899-023-00687-7 [38] Jain M D, Smith M, Shah N N. How I treat refractory CRS and ICANS after CAR T-cell therapy[J]. Blood, 2023, 141(20): 2430-2442. DOI: 10.1182/blood.2022017414 [39] Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6): 739-748. DOI: 10.1038/s41591-018-0036-4 [40] Sterner R C, Sterner R M. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy[J]. Front Immunol, 2022, 13: 879608. DOI: 10.3389/fimmu.2022.879608 [41] Suarez Montero J C, Caballero Gonzalez A C, Aguilar L M, et al. Immune effector cell-associated neurotoxicity syndrome: a therapeutic approach in the critically ill[J]. Med Intensiva(Engl Ed), 2020: S0210-5691(20)30244-8. DOI: 10.1016/j.medin.2020.06.014 [42] Wehrli M, Gallagher K, Chen Y B, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome(ICANS)[J]. J Immunother Cancer, 2022, 10(1): e003847. DOI: 10.1136/jitc-2021-003847 [43] 施婷婷, 卢根. 儿童呼吸道过敏性疾病与感染[J]. 中华实用儿科临床杂志, 2021, 36(6): 452-456. DOI: 10.3760/cma.j.cn101070-20201014-01620 [44] Wudhikarn K, Perales M A. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy[J]. Bone Marrow Transplant, 2022, 57(10): 1477-1488. DOI: 10.1038/s41409-022-01756-w [45] Shimabukuro-Vornhagen A, Böll B, Schellongowski P, et al. Critical care management of chimeric antigen receptor T-cell therapy recipients[J]. CA Cancer J Clin, 2022, 72(1): 78-93. DOI: 10.3322/caac.21702 [46] Vora S B, Waghmare A, Englund J A, et al. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults[J]. Open Forum Infect Dis, 2020, 7(5): ofaa121. DOI: 10.1093/ofid/ofaa121 [47] Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality[J]. Blood Adv, 2020, 4(13): 3024-3033. DOI: 10.1182/bloodadvances.2020001972 [48] Moturi K R, Lingamaneni P, Baral B, et al. Temporal trends in inpatient outcomes and resource utilization in patients with tumor lysis syndrome(TLS)with solid and hematologic cancers: a nationwide analysis[J]. J Clin Oncol, 2020, 38(15_suppl): e19102. DOI: 10.1200/jco.2020.38.15_suppl.e19102 [49] Umair M M, Lai X, Xue Y B, et al. Influence of CAR T-cell therapy associated complications[J]. Front Oncol, 2025, 15: 1494986. DOI: 10.3389/fonc.2025.1494986 [50] Cappell K M, Kochenderfer J N. Long-term outcomes following CAR T cell therapy: what we know so far[J]. Nat Rev Clin Oncol, 2023, 20(6): 359-371. DOI: 10.1038/s41571-023-00754-1 [51] Brudno J N, Natrakul D, Lam N, et al. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms[J]. Leuk Lymphoma, 2022, 63(8): 1849-1860. DOI: 10.1080/10428194.2022.2056172 [52] Strati P, Varma A, Adkins S, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma[J]. Haematologica, 2021, 106(10): 2667-2672. DOI: 10.3324/haematol.2020.254045 |
| [1] | WANG Tan, WU Ke, LI Lianqing, GONG Lili. Factors associated with systemic adverse reactions after subcutaneous immunotherapy injections and treatment options [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 71-74. |
|
||